Illumina Inc. (NASDAQ ... delivering the NovaSeq X single-flow-cell system alongside a cutting-edge software upgrade and new kits.

Grail’s cutting-edge cancer blood test has stirred investor excitement many times in the past few years. With the stock down 55% from its February peak, Canaccord Genuity issued a Buy recommendation ...

Illumina is teaming up with Tempus AI for a project aimed at promoting the use of DNA sequencing tests across all major areas ...

SAN DIEGO and CHICAGO - Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM) today announced a partnership aimed at advancing the use of artificial intelligence (AI) in genomic ...

The Global Single Cell Analysis Market achieved a valuation of $4.90 Billion in 2024 and is anticipated to exceed $21.97 ...

Bernstein lowered the firm’s price target on Illumina (ILMN) to $90 from $130 and keeps a Market Perform rating on the shares. With tariffs, concerns about NIH and broader academic/government ...

Genomic testing market was valued at US$ 14.51 billion in 2023 and is projected to attain a valuation of US$ 32.95 billion by 2032, at a CAGR of 9.54% during the forecast period, 2024-2032.

Shear flow systems can reveal in vivo-like changes in cell growth, adhesion and movement not observed in static assays, effectively emulating in vivo conditions and revealing true biology. In this ...

There was a issue that came aboard due to a customer representative reloading a payment into 1 account. After so many representative and supervisors to repeat self to about the situation no one ...